Research progress in c-Met and hepatocellular carcinoma / 临床肝胆病杂志
Journal of Clinical Hepatology
; (12): 982-2015.
Article
in Zh
| WPRIM
| ID: wpr-778057
Responsible library:
WPRO
ABSTRACT
c-Met plays a pivotal role in the development and progression of hepatocellular carcinoma (HCC), which can lead to proliferation, survival, cytoskeleton reorganization, separation and diffusion, and angiogenesis of tumor cells. Moreover, c-Met is an important prognostic factor for HCC. In HCC, c-Met acts as an activator of a series of signaling pathways, including PI3K/AKT/mTOR, ERK/MAPK, and Rac-Pak. In recent years, it has been reported that small-molecule kinase inhibitors can abolish phosphorylation at the intracellular carboxyl terminal of c-Met, and then inhibit the recruitment of signal convertors and downstream signaling pathways, which finally achieve anti-tumor activities. Based on the carcinogenic activity of c-Met in HCC, this paper points out that selective inhibitors of c-Met hold promise for targeted therapies for HCC.
Full text:
1
Index:
WPRIM
Type of study:
Prognostic_studies
Language:
Zh
Journal:
Journal of Clinical Hepatology
Year:
2015
Type:
Article